Why Eli Lilly and Company (LLY) stock moved
Eli Lilly and Company (LLY) shares rose 3.2% to $1,417.54 as of October 31, 2026, a moderate gain from the prior close of $1,373.70. BestStocks flagged the session as a major change for LLY. Below, we break down what changed for LLY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
LLY climbed 3.2% to $1417.54
LLY rose 3.2% in its latest session, moving from $1,373.70 to $1,417.54.
What it means for Eli Lilly and Company investors
For Eli Lilly and Company investors, the balance of recent signals points to a strong bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 3.2% session move. Weighing against that: New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in LLY's fundamentals. Wall Street's consensus price target sits at $1,433.72, implying +1.1% upside from $1,417.54. BestStocks rates the overall signal quality medium (67/100). With earnings roughly 95 days out, the next report is the most likely near-term test of the move.
LLY price reaction
LLY last traded at $1,417.54, up $43.84 (+3.19%) from the previous close of $1,373.70. The session traded on 1.9× average volume (above avg), so the move carried above-average conviction. Its healthcare peer group moved a median +1.4% over the same stretch, leaving LLY ahead of the group by 1.8 points. Over the past month the stock has ranged between $1,142.85 and $1,417.54, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Eli Lilly and Company (LLY)
The consensus analyst price target on Eli Lilly and Company (LLY) is $1,433.72, 1.1% above the recent $1,417.54. Over the past 90 days analysts logged 0 upgrades, 20 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LLY line up.
The bullish case
- Wall Street's consensus price target of $1,433.72 implies +1.1% upside from $1,417.54.
- The Street's most bullish target is $1,650.00 (+16.4%).
- Earnings beat with positive market reaction.
- Positive 3.2% session move.
- Eli Lilly reported third-quarter revenue of $24.4 billion (+39% YoY), beating consensus of $22.58 billion, and adjusted EPS of $7.48, far exceeding the $5.68 consensus, driven by blockbuster demand for GLP-1 drugs Mounjaro and Zepbound (Barron's, Zacks).
The bearish case
- The most bearish analyst target is $940.00 (-33.7%).
Weighing both sides, BestStocks' composite read of recent signals is strongly bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 31, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LLY
In-depth LLY event analyses
Frequently asked questions about LLY
Why did Eli Lilly and Company (LLY) stock move?
LLY rose 3.2% to $1,417.54. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.
How much did LLY stock rise?
LLY gained 3.19% ($43.84) versus the prior close of $1,373.70, last trading at $1,417.54 on 1.9× average volume.
When is Eli Lilly and Company's next earnings date?
LLY's next earnings report is estimated for 2027-02-03 — about 95 days away.
What is the analyst price target for LLY?
The consensus analyst price target for LLY is $1,433.72, about 1.1% above the current $1,417.54. Over the past 90 days, analysts recorded 0 upgrades, 20 maintains, and 0 downgrades.
Is the LLY move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.4% against LLY's +3.2%. LLY ranks top 1 of 7 peers.
How BestStocks tracks LLY
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LLY-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for LLY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 31, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.